SS Innovations International, Inc. has completed a private placement generating approximately $18.6 million in gross proceeds to support its growth initiatives in the surgical robotics sector. The financing, which closed on March 6, 2026, involved the sale of 5,774,839 shares of common stock to company insiders and investors, signaling strong internal confidence in the company's future direction.
The private placement consisted of two components: company leadership purchased 1,300,006 shares at an average price of $4.00 per share, totaling approximately $5.2 million. This included investments from Chairman and CEO Dr. Sudhir Srivastava, Vice-Chairman Dr. Frederic H. Moll, and director Tim Adams. Additionally, existing and new investors purchased 4,474,833 shares at $3.00 per share, generating approximately $13.4 million, with existing shareholder Manipal Global Health Services leading this portion of the investment.
According to Dr. Srivastava, the net proceeds will advance growth initiatives in India and other existing global markets while supporting preparation for entry into the United States and European Union markets. The company anticipates that the U.S. Food and Drug Administration will complete its review of the 510(k) premarket notification for the SSi Mantra surgical robotic system by mid-2026. SS Innovations also continues along the pathway toward European Union CE marking certification, which it believes can be obtained in 2026.
The significance of this financing extends beyond immediate capital infusion. Insider participation demonstrates leadership's commitment to the company's mission of democratizing access to surgical robotic care. Dr. Srivastava noted that this reflects strong confidence in SS Innovations' future and appreciation for the continuing support of Manipal Global Health Services, while welcoming new shareholders to the company.
For the surgical robotics industry, this development represents continued investment in technologies aimed at making robotic surgery more accessible globally. The SSi Mantra system, which has been clinically validated in India in more than 100 different types of surgical procedures, features modular robotic arms, an ergonomic surgeon command center, and utilizes over 40 different types of robotic endo-surgical instruments. More information about the company is available at https://ssinnovations.com.
The financing includes specific terms for certain investments, with SS Innovations agreeing to pay a FINRA member firm a cash commission of $175,000 (7% of a $2.5 million investment) and issue five-year warrants to purchase 41,667 shares at an exercise price of $3.45 per share. The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
This capital raise comes at a critical time for SS Innovations as it navigates regulatory pathways in major markets. Successful FDA clearance and CE marking would position the company to compete in the lucrative U.S. and European surgical robotics markets, potentially disrupting current pricing structures through its focus on affordability. The company's expansion efforts could increase global access to robotic surgical technologies, particularly in markets where cost has been a barrier to adoption.
